PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
25.8.2020 20:20:46 CEST | ViroGates | Resolutions of annual general meeting
COMPANY ANNOUNCEMENT
No. 21-2020 - 25 August 2020
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs today held its annual general meeting at the company headquarter Banevænget 13, 3460 Birkerød.
Reference is made to company announcement no. 18-2020 of 10 August 2020 setting out the agenda and complete proposals.
The following resolutions were passed:
- Attorney-at-law Nicolai Jung was elected chairman of the general meeting.
- The general meeting approved the board’s report on the company’s business for 2019
- The annual report was approved.
- It was resolved to transfer the loss for the financial year 2019 of DKK 18,797 to the next year.
- Lars Kongsbak, Lars Krogsgaard and Jørgen Thorball were were re-elected as board members. Bernd Uder resigned from the board and Henrik Stender was elected as new member of the companys’ board. Henrik Stender presented himself at the meeting. It was resolved that the remuneration for the work of the board in 2020 will be fixed at DKK 150,000 to the chairman and DKK 75,000 to each of the other directors.
- BDO Statsautoriseret Revisionsaktieselskab was re-elected as auditor for the company.
- The proposal for a new remuneration policy was approved.
- The proposal to change the keeper of the shareholders register was approved.
- The proposal to allow general meetings by way of electronic communication was approved.
- Nothing was resolved related to this point on the agenda
The announcement can be found at https://www.virogates.com/investor/announcements
For further information please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.
Disclaimer
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com